Background Subcutaneous injections allow for selfadministration, but consideration of patients' perspectives on treatment choice is important to ensure adherence. Previous systematic reviews have been limited in their scope for assessing preferences in relation to other routes of administration. Objective Our objective was to examine patients' perspectives on subcutaneously administered selfinjectable medications when compared with other routes or methods of administration for the same medicines. Methods Nine electronic databases were searched for publications since 2000 using terms pertaining to methods of administration, choice behavior, and adverse effects. Eligibility for inclusion was determined through reference to specific criteria by two independent reviewers. Results were described narratively. Results Of the 1726 papers screened, 85 met the inclusion criteria. Studies were focused mainly on methods of insulin administration for diabetes but also included treatments for pediatric growth disorders, multiple sclerosis, HIV, and migraine. Pen devices and autoinjectors were favored over administration with needle and syringe, particularly with respect to ergonomics, convenience, and portability. Inhalation appeared to be more acceptable than subcutaneous injection (in the case of insulin), but how subcutaneous infusion, intramuscular injection, and needlefree injection devices compare with subcutaneous injections in terms of patient preference is less certain. Conclusions The review identified a number of studies showing the importance of the methods and routes of drug delivery on patient choice. However, studies were prone to bias, and further robust evidence based on methodologically sound approaches is required to demonstrate how patient choice might translate to improved adherence.
Introduction
Patients' attitudes towards their medicines are influenced by many factors, including their perceived (or real) benefits and harms, previous experience of use, perceptions of their illness, satisfaction with treatment, and personal preferences [1] . Thus, achieving optimal treatment outcomes requires that the right patients get the right choice of medicine at the right time [2] . This notion of 'medicines optimization' also encompasses encouraging patients to take their medicines correctly, avoid taking unnecessary medicines, reduce wastage of medicines, and improve medicines safety [2, 3] . For some medicines, offering patients different methods or routes of drug administration may help achieve a patient-centered approach to care, thereby improving medication adherence, especially in the context of parenteral administration [4] [5] [6] .
While oral dosing is the method of choice for chronic disease management, it may not be possible for some medicines (e.g., because of low bioavailability) or desirable for others (e.g., because of poor targeting of the site of action). The subcutaneous route of administration is being used increasingly, particularly as alternative formulations of biologics are developed for conditions such as cancers and inflammatory diseases [7] . Treatments including trastuzumab and rituximab-previously only available via intravenous administration-are now licensed for subcutaneous use. Compared with other routes of parenteral administration, subcutaneously injectable formulations may offer advantages in terms of convenience, ease of use, and the possibility of self-administration, which can also save health professionals time and, thus, reduce costs. However, barriers to the use of subcutaneous injections, such as anxiety [8] and adverse injection-site reactions [9] , may have a negative impact on adherence and the benefits of such treatments.
Several methods of subcutaneous administration also exist, and patients' satisfaction with, or preferences towards, delivery devices are likely to differ. In the case of insulin, for instance, patients consider pen devices to be a more acceptable method of administration than conventional vial and syringe or pre-filled syringes [10] . These offer improved portability, convenience, ease of use, and reduced injection-site pain, leading to better patient satisfaction. Compared with vials and syringes, insulin pen devices may consequently improve adherence and reduce healthcare resource use and associated costs [11] .
Whilst differences in the pharmacokinetics and efficacy of competing methods and routes of drug administration are well documented, less is known of patients' perspectives. Relevant research methods include the use of selfreported outcomes, such as from rating and ranking scales, willingness-to-pay studies, discrete-choice experiments, conjoint analyses, and best-worst scaling exercises.
This review aims to examine patients' perspectives on subcutaneously administered self-injectable medications. It focuses on study methodologies and on examining how patients' choices compare for different devices and routes of administration.
Methods
The systematic review protocol was registered with the All Wales Systematic Reviews Register [12, 13] , conducted according to the methods of the Centre for Reviews and Dissemination [14] , and reported according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement [15] .
Sources Searched
The following databases were searched during July 2013, using a combination of medical subject headings (MeSH) and free-text searches: Embase (Ovid), CINAHL (EBSCO Host), PubMed, Cochrane (including the Cochrane Database of Systematic Reviews), TOXLINE (ProQuest), PsycARTICLES (ProQuest), PsycINFO (ProQuest), Health & Safety Science Abstracts (ProQuest), Physical Education Index (ProQuest).
Search Terms
Free-text or MeSH heading terms pertaining to (1) the route of administration were combined using the Boolean operator 'AND' with terms relevant for (2) identifying choice behavior and methods of elicitation, and (3) (perceived) adverse injection-site reactions or process utility: 
Inclusion Criteria
Studies were included if they reported on a comparison(s) of subcutaneous administration of a medicinal product versus a different route of administration or using a different subcutaneous device, including hypothetical scenarios; in patients currently or likely to become responsible for self-administration of subcutaneous medication; and which measured patients' perspectives towards to the health technology, adverse effects attributable to the method/route of administration such as pain or injectionsite reactions, or satisfaction.
Exclusion Criteria
Studies were excluded if they were published prior to 2000; written in a language other than English; were reviews, case studies, decision models, news, correspondence, or commentaries; were published as conference abstracts or posters or in books or trade journals; were animal, mechanistic, or pharmacokinetic studies; assessed vaccines, anesthesia or palliative care; or considered injection drug users or non-ambulatory patients.
Review Methods
Titles and abstracts were read and eligibility was assessed independently by two reviewers. The full manuscripts of potentially eligible studies were retrieved and assessed by both reviewers against the inclusion and exclusion criteria. Disagreements in the application of inclusion or exclusion criteria were resolved by consensus and/or consultation with two other reviewers.
Outcome Measures
A wide range of outcomes was considered, to reflect the various dimensions that influence patient choice: (1) Health technology-related outcomes (including ease of use, portability and convenience); (2) Behavioral outcomes (including perceived benefits, perceived barriers, satisfaction, and fear/discomfort of needles); (3) Adverse reactions (including fear of pain and injection-site reactions).
Data Extraction
Data were extracted on (1) description of study; (2) characteristics of the population and intervention; (3) types of outcome measures; (4) any measured revealed preferences (adherence); (5) comparators; (6) study type; (7) results; and (8) characteristics of study sponsors and links to authors.
Data Analysis
Results were primarily presented narratively [14] , with strength of patients' choices assessed from the statistical significance reported or inferred from individual studies. The potential to perform a quantitative (meta)-analysis was specified a priori, conditional on a rigorous assessment of clinical, methodological, and statistical heterogeneity between studies. We were cognizant of the dangers of synthesizing results from diverse studies as this can lead to biased assessments and give rise to misleading results. We therefore limited any quantitative analysis of the data to studies that (1) compared a common drug, (2) made the same comparison among two (or more) devices/routes of administration (we excluded studies in which comparators were not described in full), (3) reported a common outcome, and (4) used a common method of assessing outcomes (methods that were not validated or not reported were excluded). Meta-analyses of eligible studies were performed in RevMan version 5 (Cochrane Collaboration) using random-effects modelling to assess the pooled mean difference (for continuous variables) or odds ratio (for dichotomous variables).
Results

Number of Studies
A total of 2337 articles relating to patient preferences for subcutaneous medications were identified. Following deduplication and screening, 85 were judged suitable for inclusion. The PRISMA flow diagram of the search and screening process is presented in Fig. 1 . A summary of the main characteristics of each paper is presented in Appendix 1 of the Electronic Supplementary Material (ESM).
Study Populations
Sample sizes ranged from 19 to 6528 people. The majority involved administration of insulin for the management of diabetes (n = 51 studies), followed by growth hormone deficiency (n = 10), migraine (n = 5), and multiple sclerosis (n = 4). Other areas included HIV, infertility, contraception, chronic kidney disease, and rheumatoid arthritis. The age range of patients from whom views were obtained directly was 3.5-95 years.
Study Characteristics
The studies described 102 separate comparisons (Fig. 2) , with the majority considering alternative means of subcutaneous administration (Table 1) . For 16 comparisons, no details were provided on the type of subcutaneous device, and a further 16 comparisons involving insulin provided incomplete information on how multiple daily injections (MDIs) were achieved.
A variety of study designs were described: 43 were randomized studies, 29 were cross-over trials, and 18 were parallel-arm studies. The duration of clinical studies ranged from 1 week to 2 years. The majority used generic or disease-specific questionnaires; 16 used open-ended questioning or semi-structured interviews. Nine studies used Likert scales, and 12 studies used other rating scales, including a visual analog scale. Five studies sought to elicit stated preferences for routes of administration using choice-based methods, including discrete-choice experiment (DCE), adaptive conjoint analysis (ACA), and time trade-off (TTO) analysis. Some studies used simulated injections to obtain information on ease of administration. Table 2 summarizes the methods used to elicit preference.
The majority of studies stated links with one or more organizations likely to have commercial interest in the outcomes. The level of involvement ranged from provision of specific costs, such as translation or equipment, to direct study funding and/or authorship, provision of grants, or an author being an advisory board member.
Main Study Findings
Results from four studies comparing subcutaneous administration with intramuscular injection [16] [17] [18] [19] were mixed. While one observational study of interferon-beta-1a in patients with multiple sclerosis found a significant difference in patients' desire to change or discontinue treatment adherence at 1 year in favor of intramuscular injection, with the number of injection-site reactions reported as an important factor [16] , another suggested a preference towards subcutaneous administration [17] . The findings of two studies of the contraceptive medroxyprogesterone acetate were similarly inconclusive, with one indicating a tendency towards higher satisfaction with subcutaneous administration [18] , and the other showing no statistically significant difference in in reported measures of satisfaction [19] .
Inhaled insulin was preferred to subcutaneous insulin in all included studies [20] [21] [22] [23] [24] [25] [26] . However, all studies reported ties with the manufacturers of inhaled insulin technologies. The possibility of publication bias could not be rejected.
Comparisons of subcutaneous injection with oral administration did not reveal any statistically significant differences in preference. In two surveys presenting hypothetical scenarios to patients with migraine, there was a tendency for the oral route being preferred, [31] and for formulation type to be more important than speed of onset [27] . However, two clinical comparisons of sumatriptan suggested the opposite, with a subcutaneous formulation tending to be preferred [28, 29] . A DCE among patients with osteoporosis indicated that patients would be willing to pay €142 a month for a daily subcutaneous injection rather than a daily or weekly tablet [30] .
Four of the comparisons of oral and subcutaneous formulations in migraine also considered nasal administration, but none demonstrated any statistically significant difference in preference [27] [28] [29] 31] .
Two studies compared subcutaneous with transdermal administration [31, 32] . In a cross-over study of insulin delivery, significantly more patients with type 1 or 2 diabetes stated that they would switch to a patch treatment, if available [32] .
Among studies comparing needle-free injector devices (NFIDs) with subcutaneous injections, four compared enfuvirtide delivered via NFID and needle and syringe in patients with HIV. All found significant differences in favor of NFID in terms of patient-rated ease of use [33] , preference [35] , or a desire to continue with the NFID at the end of the study [34, 36] . However, there was no significant difference in patient satisfaction among women Fig. 1 The PRISMA flow diagram of the search and screening process. SC subcutaneous self-administering gonadotropin for infertility treatment [37] or in three studies of children receiving growth hormone therapy [38] [39] [40] . Nine comparisons of autoinjector devices versus vial and syringe and/or pre-filled syringes (PFS) or other autoinjectors were identified. An ACA of users of growth hormone therapy revealed autoinjection generated higher utility [38] . Autoinjectors for adalimumab were preferred to PFS and associated with less injection-site pain in patients with rheumatoid arthritis [41, 42] . Autoinjectors were similarly preferred for darbepoetin in chronic kidney disease [43] and for sumatriptan in migraine [48] . While one study of autoinjector devices for growth hormone found a preference among both patients and parents [45] , another found less favorable scores compared with pen devices, largely due to the requirement for reconstitution [44] . Studies of interferon-beta-1a autoinjectors in multiple sclerosis yielded varying results. One found no significant changes from baseline in a disease-specific treatment concern questionnaire [46] , while another suggested a preference for autoinjectors [47] .
Of 12 papers investigating insulin via subcutaneous catheter (mainly continuous subcutaneous infusion) compared with MDI [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] , nine found significant differences in favor of administration by infusion, through a range of largely disease-specific measures [49] [50] [51] [52] [53] [54] [57] [58] [59] .
A total of 18 studies compared subcutaneous administration using pen devices with syringes, 17 using traditional syringe and vial. These were largely for insulin in diabetes, but also for psoriasis treatment [61] , growth hormone deficiency [62] , infertility [63, 64] , and hepatitis C [65] . Pens were significantly preferred in 15 studies, particularly The largest number of comparisons was between different pen devices, including 22 for administration of insulin [74, 75, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] , and four for growth hormone [97] [98] [99] [100] . However, 13 insulin and three growth hormone studies used simulated injections, and no clinical study of pen devices was for longer than 12 weeks. All claimed advantages for the novel device over comparators, with statistically significant differences in 19; however, all were authored and/or sponsored by manufacturers. IFNb-1a/multiple sclerosis [16, 17] ; medroxyprogesterone acetate/contraception [18, 19] Wanting to switch or discontinue therapy [16] ; preference [17] ; theoretical preference [18] ; satisfaction [19] Inhalation (n = 7, 6 studies)
Insulin/diabetes [20] [21] [22] [23] [24] [25] [26] Satisfaction [20-22, 25, 26] ; theoretical preference [23] ; theoretical choice of therapy [24] Oral (n = 5) Theoretical/migraine [27, 31] ; sumatriptan/migraine [28, 29] ; theoretical/osteoporosis [30] Willingness to pay [30] Theoretical preference [27, 31] ; preference [28] ; preference and satisfaction [29] Nasal (n = 4)
Theoretical/migraine [27, 31] ; sumatriptan/migraine [28, 29] Theoretical preference [27, 31] ; preference [28] ; preference and satisfaction [29] Transdermal (n = 2) Theoretical/migraine [31] ; insulin/diabetes [32] Theoretical preference [31] Satisfaction and wish to switch [32] SC needle free (n = 8)
Enfuvirtide/HIV [33] [34] [35] [36] ; gonadotropin/infertility [37] ; growth hormone [38] [39] [40] Ease of use [33] ; wish to continue [34, 36] ; preference [35] Concern about pain and fear of needles [37] ; conjoint analysis trade-off [38] ; wish to continue [39] ; reasons for choice [40] SC autoinjector (n = 9)
Growth hormone [38, 44, 45] ; adalimumab/rheumatoid arthritis [41, 42] ; darbepoetin alfa/chronic kidney disease [43] ; IFNb-1a/ 1b/multiple sclerosis [46, 47] ; sumatriptan/migraine [48] Less pain, preference [41] ; preference [42, 43, 45] ; ease of use [47] ; singledose usability preference [48] Conjoint analysis trade-off [38] ; usability [44] ; suitability [46] SC infusion/ indwelling catheter (n = 12)
Insulin/diabetes [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Preference [49] ; Diabetes Treatment Satisfaction Questionnaire [50] [51] [52] [53] [57] [58] [59] ; anxiety and pain [54] Satisfaction [55, 60] ; preference during study [56] Pen devices vs.
Etanercept/psoriasis [61] ; growth hormone [62] ; gonadotropin/ infertility [63, 64] ; IFNa-2b/ chronic hepatitis C [65] ; insulin/diabetes [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] Satisfaction [61] ; preference [62, 63, 66-68, 70, 71, 74, 76, 77] ; convenience [64] ; ease of use [69, 72] Satisfaction [65] ; convenience [73] ; ease of use [75] Other pen devices (n = 26)
Various insulin/diabetes [74, 75, 77] ; growth hormone [97] [98] [99] [100] Preference [74, 77-81, 83-85, 87, 88, 90-93, 95-97, 99] Ease of use [75] ; satisfaction [82] ; preference [86, 89, 94, 98, 100] Results presented in the final three columns indicate, respectively, dimensions of outcome reported to be significantly favored for the reference product, no difference between reference and comparator (or no significance reported), and significantly favoring the comparator (as detailed in the first column)
HIV human immunodeficiency virus, IM intramuscular, SC subcutaneous Among all the studies examined, only 12 assessed adherence or persistence as a revealed preference [16, 19, 26, 35, 36, 40-42, 62, 65, 71, 73] , and most of these relied on patient self-report.
Meta Analyses
Four groups of studies were considered eligible for metaanalyses, each of which compared insulin delivered using pen devices versus some alternative method (see Appendix 2 in the ESM). These were (1) the assessment of patients' satisfaction compared with continuous subcutaneous infusion [51, 57] , (2) patient preference for a new pen device versus their existing pen device [80, 81, 83, 92, 94] , (3) preference compared with subcutaneous needle and syringe [68, 71] , and (4) preferences in comparison with any existing method of administration [74, 78, 79] .
The comparison of pen devices with subcutaneous needle and syringe yielded a pooled odds ratio of 6.7 (95 % confidence interval 4.6-9.7; heterogeneity I 2 = 0 %) for patients favoring pen devices. However, as this represented only 2 of 13 studies making this comparison, the potential for selection bias cannot be excluded. All other comparisons were statistically heterogeneous (I 2 C 98 %) and therefore deemed unreliable.
Discussion
An understanding of patients' perspectives on the methods and routes of drug delivery is an important consideration for maximizing the effectiveness of medicines. Our systematic review identified wide-ranging evidence using a range of methods of assessing patients' stated and actual choice for subcutaneous versus alternative routes of drug administration, as well as between different subcutaneous injectable devices. The principal findings were increased satisfaction and preferences with respect to the ergonomics, convenience, and portability of insulin pen devices and autoinjectors as compared with needle and syringe, and more satisfaction with inhaled insulin; but no clear favoring of oral, subcutaneous infusion, intramuscular injection, and NFIDs when compared with subcutaneous injections.
A significant number of studies meeting our inclusion criteria investigated methods of insulin delivery, reflecting developments in pen devices and the (now discontinued) inhaler, Exubera. Satisfaction with and preference for different insulin devices and routes of administration may relate more to the need for a convenient and pain-free method, given the need for punctual and life-long therapy. By contrast, studies in migraine, where the need for medication is intermittent and unpredictable, having available options of administration routes for use in different circumstances may be more important to patients than any single preferred option. These contrasts suggest that factors important for patient choice of a given route of administration will vary with the clinical situation and context of use.
The number of studies comparing subcutaneous administration with oral, nasal, transdermal, and intramuscular administration were each very small and covered different therapeutic areas. None of the studies compared subcutaneous self-administration with intravenous administration by healthcare professionals in a clinical setting, which we perceive to be increasing with the introduction of novel biologic therapies. The comparison with clinic-administration by intramuscular injection of medroxyprogesterone acetate as a contraceptive was perhaps the closest situation, but neither study revealed any difference from a patient's perspective [18, 19] . IM intramuscular, IV intravenous, M/Q measure/questionnaire, NR not reported, SC subcutaneous Whilst our review complied with best methodological practice, the strength of our findings is limited by the weaknesses of the research identified and the variety of approaches employed. The number of studies comparing subcutaneous injection with non-subcutaneous routes was small for each route, and many studies were observational, unmasked, and had small sample sizes and short follow-up periods. The descriptions of the technologies being assessed or of the methods of analysis were generally inadequate. Although some studies did not disclose a source of funding, the majority were supported by (or linked to) pharmaceutical companies seeking to differentiate their products from those of competitors. As more biopharmaceutical products are developed and treatments previously administered intravenously are formulated for subcutaneous administration, more patient-centered evaluations are likely to emerge; however, this should not be at the expense of methodological rigour.
Reviewed studies employed a range of methods, including direct questioning of patients, typically with responses on Likert scales, for their satisfaction with or preference for different treatment options. Such surveys employed a variety of questionnaire designs, only some of which were recognized as validated. The DCEs or conjoint analyses employed in a small number of studies are a more appropriate choice-based method of preference elicitation grounded in theory [101] . There was considerable heterogeneity among studies, in terms of populations, treatments, methods of drug administration, and outcome measure and measurement, to enable unbiased pooled estimates to be determined through meta-analyses in all but one comparison [102] . Combining heterogeneous studies could compromise the systematic and scientifically rigorous representation of empirical evidence that could be more accurately reported in our narrative synthesis [14] .
Our systematic review has extended previous reviews [10, 103] , which were restricted to comparisons of pen versus needle and syringe insulin for diabetes. Our findings suggest that differences in patients' perspectives between methods and routes of drug delivery will affect choice of delivery device across a whole spectrum of diseases. But while evidence of patient preference-in addition to all features/attributes of medicines (such as efficacy, safety, route of administration)-may potentially add value to treatments, health technology assessments require evidence on how this improves health outcomes and/or cost effectiveness to justify any increases in pricing. These were outside the scope of the present review; however, even so, very few studies considered patient adherence to treatment that might mediate improvements in health outcomes.
The implications of our findings are first that medicines may be optimized by considering patient choice in the clinical decision to prescribe a particular method or route of administration. Prescribers should be alert to the alternative options for subcutaneously administered medicines and consider the range of factors that are likely to influence patients' adherence with treatment. Second, pharmaceutical companies often cite patient preference as a justification for price premiums. Their value dossiers and health technology assessment reports typically suggest that patients favor some methods or drug administration routes over others and that this can lead to improvements in health outcomes. Our review illustrates that evidence underpinning such claims is weak.
Conclusions
Our review identified a number of studies showing the importance of the methods and routes of drug delivery on patient choice. However, to improve the evidence base, we propose that future studies of patients' perspectives of injectable devices should consider using validated preference measures combined with a choice-based experiment for stated-preference elicitation, and reliable adherence measurement [5] for revealed preferences. Studies need to be unbiased and appropriately powered for demonstrating statistical significance. Contributions CR and DH contributed substantially to the conception and design of the work. All authors made contributions to the acquisition, analysis, or interpretation of data. CR and LT drafted and DH redrafted the paper; all authors revised it critically for important intellectual content, and gave their final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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